[A20-115] Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2021
Commission awarded on 03.12.2020 by the Federal Joint Committee (G-BA).
Maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Hint of lesser benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.